JNJ-61393215

DRUG6 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

HealthyMajor Depressive Disorder With Anxious Distress

Phase 1

Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants

CompletedNCT02812251

Janssen-Cilag International NVHealthy

Start: 2016-07-07End: 2016-11-17Updated: 2025-04-27

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants

CompletedNCT03007693

Janssen Research & Development, LLCHealthy

Start: 2017-01-31End: 2017-10-31Updated: 2025-04-27

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

CompletedNCT03593954

Janssen Research & Development, LLCHealthy

Start: 2018-07-31End: 2018-09-19Updated: 2025-04-27

A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

CompletedNCT03649997

Janssen Research & Development, LLCHealthy

Start: 2018-08-28End: 2018-12-14Updated: 2025-04-27

A Study of JNJ-61393215 in Healthy Japanese Male Participants

CompletedNCT04713930

Janssen Pharmaceutical K.K.Healthy

Start: 2021-01-29End: 2021-05-31Updated: 2025-04-28

Phase 2

A Study of JNJ-61393215 in the Treatment of Depression

CompletedNCT04080752

Janssen Research & Development, LLCMajor Depressive Disorder With Anxious Distress

Start: 2019-09-17End: 2021-09-02Updated: 2025-04-29

Related Papers

Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study.

2025-04-132 citations

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time.

2022-01-154 citations